Consolidated Revenue Growth
Consolidated revenue grew 6% FX-neutral in Q4 2025 and 4% for the full year 2025, driven by strong performance in Peru (+11% in the quarter) and Colombia (+6% in the quarter).
Material Improvement in Adjusted Net Income
Adjusted net income rose to PEN 136 million in Q4 2025 from PEN 36 million a year earlier (more than 3x increase in the quarter) and reached PEN 336 million for the full year 2025, supported by noncash FX gains and improved financial discipline.
Peru Outperformance and Margin Expansion
Peru delivered strong results: quarterly revenue +11%, adjusted EBITDA +14% (quarter and full year), Oncosalud revenues +10%, planned memberships up ~4%, and oncology medical loss ratio (MLR) improved to a record low of 48.5% (down ~4.4 percentage points).
Free Cash Flow and Liquidity Strengthening
Free cash flow grew 35% to PEN 582 million and year-end cash increased 42% to PEN 335 million, improving liquidity to fund strategic initiatives and deleveraging.
Debt Refinancing and Capital Structure Improvement
Executed an approximately $825 million equivalent refinancing that extended maturities, increased short-term liquidity, freed revolver capacity, lowered blended interest costs by over 100 basis points versus the old structure, and left leverage at 3.6x with a medium-term target of 3.0x net debt/EBITDA.
Positive 2026 Guidance
Management guided to 12% FX-neutral revenue growth and 12% FX-neutral adjusted EBITDA growth for 2026, with CapEx expected around 4% of revenue, reflecting confidence in recovery initiatives and disciplined cost management.
Mexico Operational Stabilization and Oncology Momentum
Mexico operations were described as stabilized: revenues were flat sequentially (Q4 vs Q3) though down 3% YoY in local currency; oncology revenues increased 35% quarter-over-quarter, out-of-pocket revenues reached 12% of Mexico revenues in December (up from 8% in Q3), and new commercial wins (preferred provider tiers, ISSSTELEON award) should drive volumes and pricing in 2026.
Strategic Growth Opportunity — Centro Ambulatorio Trecca (Torre Trecca)
Signed a PPP to refurbish/operate a 600,000 sq ft ambulatory facility for EsSalud in Lima (serving ~3 million patients). Construction expenditures are reimbursed via progress certificates reducing capital risk; operations expected to commence H2 2028 and the asset could represent ~20–25% of Peru business at maturity.